This poor experience, combined with a commonly held view of obesity as a lifestyle choice, led many public and private insurance plans around the world to categorically exclude weight loss drugs
External links [edit source] Official website (Archive) Rite Aid Companies based in Cumberland County, Pennsylvania Companies based in Philadelphia Companies that filed for Chapter 11 bankruptcy in 2023 Companies that filed for Chapter 11 bankruptcy in 2025 American companies established in 1962 Retail companies established in 1962 American companies disestablished in 2025 Retail companies disestablished in 2025 Health care companies established in 1962 1962 establishments in Pennsylvania 2025 disestablishments in Pennsylvania Companies formerly listed on the New York Stock Exchange Health care companies based in Pennsylvania 1960s initial public offerings
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
Clinical Evidence: Weight Loss Outcomes and Effectiveness The SURMOUNT trials, which tested tirzepatide, showed average weight loss of 20.9% at the highest dose over 72 weeks, with some participants achieving losses exceeding 25%
Equally important is rebuilding resilience
